NRAS Q61

NRAS q61突变在多发性骨髓瘤、胃肠道间质瘤、黑色素瘤和其他疾病中被发现。两个黑色素瘤患者，每个人在这个基因座（Q61L和Q61R）都有突变，对Akylating剂替莫唑胺治疗有反应。然而，在结直肠癌患者中，这一基因座的突变被证明具有抗西妥昔单抗的作用。该位点突变的预后影响目前正在研究中。
NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.